<DOC>
	<DOCNO>NCT00562198</DOCNO>
	<brief_summary>This open , randomised , active-controlled , 2-period crossover study compare effect single dose Stalevo 200 Sinemet striatal ( putamenal caudate ) 11C-raclopride BP PD patient wearing-off symptom . The study consist 4 visit : screen visit ( visit 1 ) , 2 treatment period ( period 1=visit 2 , period 2=visit 3 ) separate minimum wash-out period least 3 day , end-of-study visit ( visit 4 ) . Subjects randomly allocate start period 1 single dose Stalevo 200 Sinemet . After wash-out study drug period 2 administer accord crossover design .</brief_summary>
	<brief_title>PET-Study : Effects Single Doses Stalevo Levodopa/Carbidopa Striatal 11C-Raclopride Binding</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Raclopride</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>1 . Male female patient idiopathic Parkinson 's disease accord UK Brain Bank criterion . 2 . Predictable wearingoff symptom response standard release levodopa/carbidopa ( 200/50 mg ) levodopa challenge test last minimum 1.5 h maximum 4 h. 3 . The magnitude response ( peak effect ) levodopa challenge test least 30 % . The magnitude response define difference baseline score low UPDRS III score levodopa challenge test . 4 . Hoehn Yahr stage least 2.0 perform `` ON '' state . 5 . Treatment least 4 daily dos levodopa/dopa decarboxylase inhibitor ( DDCI ) ( ± entacapone ( Comtess® Stalevo ) total daily levodopa dose range 4001200mg . 6 . Unchanged levodopa/DDCI ± entacapone antiparkinsonian medication [ dopamine agonist , monoamine oxidase B ( MAOB ) inhibitor , amantadine and/or anticholinergic approve dose ] , , least 2 week prior period I . 7 . Written inform consent obtain . 8 . Age 4580 year , inclusive . 1 . Secondary atypical parkinsonism . 2 . Patients unpredictable `` OFF '' period . 3 . Patients moderate severe treatmentrelated peakdose dyskinesia likely affect quality brain magnetic resonance image ( MRI ) positron emission tomography ( PET ) imaging . 4 . Failure adequately respond levodopa ( levodopa/carbidopa 200/50 mg ) challenge test duration response last less 1.5 h 4 h. 5 . Presence basal ganglia lesion MRI image factor ( ) would make MRI PET image likely unsatisfactory . 6 . Presence ferromagnetic object would make brain MRI imaging contraindicate . 7 . Patients history laboratory abnormality consistent , clinically significant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , neurological psychiatric disorder major concurrent illness , may influence outcome study include interpretation usage MRI PET image study purpose . 8 . History neuroleptic malignant syndrome ( NMS ) and/or nontraumatic rhabdomyolysis , malignant melanoma , narrowangle glaucoma pheochromocytoma . 9 . Severe hepatic impairment . 10 . Any abnormal electrocardiogram ( ECG ) find clinical relevance . 11 . Female patient childbearing potential ( menstruate less 2 year postmenopausal ) use adequate contraception study ( define hormonal contraception , intrauterine device surgical sterilization ) female patient pregnant lactate . 12 . Treatment cabergoline . 13 . Concomitant treatment apomorphine , MAOA inhibitor nonselective MAO inhibitor . 14 . Concomitant treatment drug antidopaminergic action ( e.g . D2 receptor block property ) less two week within five time elimination halflife give drug prior first study drug administration . As exception , use domperidone allow . 15 . Current , regular use iron preparation interrupt duration study 16 . Patients likely need rescue dose levodopa withdrawal levodopa/DDCI ± entacapone medication prior PET image . 17 . Known hypersensitivity active study drug substance excipients . 18 . Participation drug study within 30 day prior study entry . 19 . Blood donation loss significant amount blood within 60 day prior screen . 20 . Any condition opinion investigator could create hazard subject safety , endanger study procedure interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>